

21 Sept 2022

To Whom It May Concern:

Seagen Inc. is committed to the disclosure of clinical trial results conducted in the EU & EEA per the requirements of Commission Guideline 2012/C 302/03. The trial listed below was registered with the EudraCT database but was not initiated / was withdrawn prior to enrollment of any EU participants.

Please consider this as notice to close this EudraCT record:

EudraCT#	Study Title	Sponsor Code	Sponsor Name
2019-003982-17	A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy	SGN35-015	Seagen Inc.